Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Non-Current Deferred Tax Liability (2016 - 2025)

Gsk has reported Non-Current Deferred Tax Liability over the past 10 years, most recently at $387.1 million for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $387.1 million for Q4 2025, down 21.05% from a year ago — trailing twelve months through Dec 2025 was $387.1 million (down 21.05% YoY), and the annual figure for FY2025 was $387.1 million, down 21.05%.
  • Non-Current Deferred Tax Liability for Q4 2025 was $387.1 million at Gsk, down from $490.3 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for GLAXF hit a ceiling of $4.8 billion in Q4 2021 and a floor of $339.0 million in Q4 2022.
  • Median Non-Current Deferred Tax Liability over the past 5 years was $387.1 million (2025), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: tumbled 92.93% in 2022 and later increased 27.02% in 2024.
  • Gsk's Non-Current Deferred Tax Liability stood at $4.8 billion in 2021, then tumbled by 92.93% to $339.0 million in 2022, then rose by 13.87% to $386.0 million in 2023, then rose by 27.02% to $490.3 million in 2024, then decreased by 21.05% to $387.1 million in 2025.
  • The last three reported values for Non-Current Deferred Tax Liability were $387.1 million (Q4 2025), $490.3 million (Q4 2024), and $386.0 million (Q4 2023) per Business Quant data.